Wildy Logo
(020) 7242 5778
enquiries@wildy.com

Book of the Month

Cover of Company Directors: Duties, Liabilities and Remedies

Company Directors: Duties, Liabilities and Remedies

Edited by: Mark Arnold KC, Simon Mortimore KC
Price: £275.00

Lord Denning: Life, Law and Legacy



  


Welcome to Wildys

Watch


NEW EDITION Pre-order Mortgage Receivership: Law and Practice



 Stephanie Tozer, Cecily Crampin, Tricia Hemans
Practical guidance to relevant law & procedure


Offers for Newly Called Barristers & Students

Special Discounts for Newly Called & Students

Read More ...


Secondhand & Out of Print

Browse Secondhand Online

Read More...


Easter Closing

We will be closed between Friday 29th March and Monday 1st April for the Easter Bank Holidays, reopening at 8.30am on Tuesday 2nd April. Any orders received during this period will be processed with when we re-open.

Hide this message

Intellectual Property and Biotechnology


ISBN13: 9781848442610
Published: July 2011
Publisher: Edward Elgar Publishing Limited
Country of Publication: UK
Format: Hardback
Price: £260.00



Despatched in 2 to 4 days.

In this timely volume Professor Arti Rai brings together a wide range of articles that reveal the important role of intellectual property law in the formation and development of the dynamic and economically significant biotechnology industry. The collection encompasses theoretical articles that present principles of patent economics important to the industry, articles that discuss the patent law doctrines most relevant to biotechnology and empirical studies on the 'real world' effects of patents and secrecy. These are resonant issues in an ever-expanding field, and will establish this book as an essential reference point for lawyers, researchers and students.

Subjects:
Intellectual Property Law
Contents:
Introduction Arti K. Rai PART I THE LAW AND ECONOMICS OF BIOTECHNOLOGY PATENTS: FIRST PRINCIPLES A. Foundational Technologies 1. Edmund W. Kitch (1977), 'The Nature and Function of the Patent System' 2. Robert P. Merges and Richard R. Nelson (1990), 'On the Complex Economics of Patent Scope' B. Anti-commons 3. Michael A. Heller and Rebecca S. Eisenberg (1998), 'Can Patents Deter Innovation? The Anti Commons in Biomedical Research' 4. John P. Walsh, Ashish Arora and Wesley M. Cohen (2003), 'Working Through the Patent Problem' 5. Fiona Murray and Scott Stern (2007), 'Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-commons Hypothesis' 6. Chris Holman (2006) 'Clearing a Path Through the Patent Thicket' C. Patents and Industrial Organization 7. Ashish Arora and Robert P. Merges (2004), 'Specialised Supply Firms, Property Rights and Firm Boundaries' PART II ADDRESSING TRANSACTION COSTS: THE ROLE OF THE UTILITY REQUIREMENT 8. John M. Golden (2001), 'Biotechnology, Technology Policy, and Patentability: Natural Products and Invention in the American System' PART III THE ROLE OF INSTITUTIONS: BIOTECHNOLOGY PATENTS AND THE FEDERAL CIRCUIT 9. Arti K. Rai (1999), 'Intellectual Property Rights in Biotechnology: Addressing New Technology' 10. Dan L. Burk and Mark A. Lemley (2002), 'Is Patent Law Technology-Specific?' PART IV PATENTABLE SUBJECT MATTER 11. Kevin Emerson Collins (2007), 'Propertizing Thought' PART V EXPERIMENTAL USE 12. Janice M. Mueller (2001), 'No "Dilettante Affair": Rethinking the Experimental Use Exception to Patent Infringement for Biomedical Research Tools' PART VI THE ROLE OF SECRECY AND PHYSICAL EXCLUDABILITY 13. John P. Walsh, Wesley M. Cohen and Charlene Cho (2007), 'Where Excludability Matters: Material Versus Intellectual Property in Academic Biomedical Research' PART VII COMMERCIALIZATION OF PUBLICLY FUNDED RESEARCH 14. Richard Jensen and Marie Thursby (2001), 'Proofs and Prototypes for Sale: The Licensing of University Inventions' 15. Arti K. Rai and Rebecca S. Eisenberg (2003), 'Bayh-Dole Reform and the Progress of Biomedicine' PART VIII INTELLECTUAL PROPERTY AND CONSUMER ACCESS 16. Robert Cook-Deegan, Subhashini Chandrasekharan and Misha Angrist (2009), 'The Dangers of Diagnostic Monopolies' 17. Henry G. Grabowski, David B. Ridley and Kevin A. Schulman (2007), 'Entry and Competition in Generic Biologics' Name Index